Who
Keith Regnante
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Keros Therapeutics; Chief Financial Officer, Wave Life Sciences.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $7.3M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 Aug 2016
- Last trade
- 24 Feb 2026
- Last filed
- 26 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Feb 2026filed 26 Feb 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K4,739 at $16.35 | filing |
| 18 Feb 2026filed 20 Feb 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K4,739 at $16.35 | filing |
| 18 Feb 2025filed 19 Feb 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Jan 2024filed 24 Jan 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code M | $640K40,000 at $16.00 | filing |
| 4 Jan 2024filed 24 Jan 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M40,000 at $45.29 | filing |
| 4 Jan 2024filed 8 Jan 2024 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 4 Nov 2023filed 8 Jan 2024 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code M | $640K40,000 at $16.00 | filing |
| 4 Nov 2023filed 8 Jan 2024 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M40,000 at $45.29 | filing |
| 9 Jun 2023filed 12 Jun 2023 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 9 Jun 2023filed 12 Jun 2023 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code M | $320K20,000 at $16.00 | filing |
| 9 Jun 2023filed 12 Jun 2023 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $720K15,993 at $45.03 | filing |
| 9 Jun 2023filed 12 Jun 2023 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K1,428 at $46.46 | filing |
| 9 Jun 2023filed 12 Jun 2023 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $122K2,579 at $47.25 | filing |
| 8 Jun 2023filed 12 Jun 2023 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code M | $320K20,000 at $16.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $825K17,301 at $47.66 | filing |
| 8 Jun 2023filed 12 Jun 2023 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $131K2,699 at $48.65 | filing |
News
Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Keith Regnante; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.